EBV: 95% infection can cause terminal illness and many types of cancer
- Japan Second Round of Nuclear Contaminated Water Discharge Set to Commence
- Johns Hopkins University: Early Plasma Therapy Reduces Long COVID Risk
- Ketogenic Diet Linked to Heart Diseases and Cancers
- TROP2 ADC for Breast Cancer Succeeded In Phase III Clinical Trials
- Lead Poisoning’s More Serious Impacts on Health and IQ
- Startling Link Between Alcohol and Alzheimer’s Disease
The effective vaccine against EBV may come soon
- Nearly 300 People Food Poisoning in Japanese 130-Year Restaurant
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
95% infection can cause terminal illness and many types of cancer. The effective vaccine against EBV may come soon.
Epstein Barr Virus (EBV) belongs to the herpes virus family, can be transmitted through saliva, and is known to have infected at least 95% of the adult population worldwide.
Primary Epstein-Barr virus infection can lead to glandular fever, but unlike other viruses, EBV will not be cleared by the immune system after primary infection, but will be carried for life .
EBV infection is also a risk factor for multiple sclerosis, Hodgkin’s lymphoma, and some cancers of the throat and nose. However, EBV vaccine candidates that have previously been evaluated in human and animal models have performed poorly, and currently no vaccines have shown efficacy or been approved.
On August 8, 2023, researchers from the Berghofer Institute for Medical Research in Australia published a research paper entitled: Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice in the journal Nature Communications .
The study shows that a new Epstein-Barr virus vaccine candidate has shown potential in mice . At present, there is no approved vaccine for this widespread virus, and there is an urgent global need to develop a new EBV vaccine.
The research team designed a vaccine that targets the lymph nodes and tested its efficacy in a mouse model.
They found that vaccination produced potent Epstein-Barr virus-specific antibodies and T cells that were maintained in this mouse model for at least seven months after vaccination.
Importantly, the study also demonstrated that the vaccine mobilized immunity in a mouse model of lymphoma to control the spread of Epstein-Barr virus-associated tumors and control tumor growth.
Further studies are needed to determine the efficacy of the vaccine in primary infection, how the results here translate to the human population, and the long-term stability of vaccine-induced immunity.
Paper link :
https://www.nature.com/articles/s41467-023-39770-1
95% infection can cause terminal illness and many types of cancer. The effective vaccine against EBV may come soon.
(source:internet, reference only)
Disclaimer of medicaltrend.org
